clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-106-114clinvest-540Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность и перспективы применения препарата фавипиравир у пациентов с COVID-19Current and future use of favipiravir in patients with COVID-19https://orcid.org/0000-0002-6636-3950МатвеевА. В.MatveevA. V.

Матвеев Александр Витальевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8518-1320

Москва

Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320

Moscow

https://orcid.org/0000-0002-6753-8572КиселёвЮ. Ю.KiselevYu. Yu.

Киселёв Юрий Юрьевич – PhD, доцент факультета наук о здоровье OsloMet

Осло

Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet.

Oslo

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian FederationУниверситет Осло МетрополитенНорвегияOslo Metropolitan UniversityNorway20202810202004SФармаCOVID106114Copyright © Матвеев А.В., Киселёв Ю.Ю., Сычёв Д.А., 20202020Матвеев А.В., Киселёв Ю.Ю., Сычёв Д.А.Matveev A.V., Kiselev Y.Y., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/540

Существуют экспериментальные и клинические данные касательно активности фавипиравира в отношении вируса SARS-CoV-2. Имеются сведения о значительной вариабельности фармакокинетики и соответственно с достижением необходимой подавляющей концентрации препарата. Доказательная база эффективности применения у пациентов с лёгким и среднетяжёлым течением COVID-19 ограничена открытыми рандомизированными клиническими исследованиями. Использование препарата, учитывая ограниченный опыт использования фавипиравира, требует особого внимания к безопасности его назначения (проведение теста на беременность, соблюдение контрацепции, контроль уровня мочевой кислоты, трансаминаз, ЭКГ). В настоящее время назначение препарата может быть рассмотрено лечащими врачами при преобладании предполагаемой пользы от его применения над возможными рисками в соответствии с одобренными инструкциями по медицинскому применению и временными методическими рекомендациями Минздрава России.

There are experimental and clinical data regarding the activity of favipiravir against the SARS-CoV-2 virus. The is evidence of significant variability in pharmacokinetics and associated achievement of the required inhibitory concentration of the drug. The evidence base for the effectiveness of use in patients with mild to moderate COVID-19 is limited to open-label randomized clinical trials. The use of the drug, given the limited experience of using favipiravir, requires special attention to the safety of its prescription (pregnancy test, contraception compliance, control of uric acid, transaminases, ECG). At present, the prescription of the drug can be considered by the attending physicians if the expected benefits of its use prevail over the possible risks in accordance with the approved instructions for medical use and the temporary guidelines of the Ministry of Health of Russia.

коронавирусфавипиравирCOVID-19coronavirusfavipiravirCOVID-19ReferencesГосударственный реестр лекарственных средств. Фавипиравир. [Электронный ресурс]. Доступно по: https://clck.ru/RDG2j Ссылка активна на 24.09.2020State register of medicines. Favipiravir. (In Russ). Доступно по: https://clck.ru/RDG2j Ссылка активна на 24.09.2020Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) 7-е изд., Москва: Министерство здравоохранения Российской Федерации, 2020. 166 c.The provisional guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 7th ed., Moscow: Ministry of health of the Russian Federation, 2020. 166 p. (In Russ).Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. DOI: 10.2183/pjab.93.027Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. DOI: 10.2183/pjab.93.027Du Y, Chen X. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020 Aug;108(2):242-247. DOI: 10.1002/cpt.1844Du Y, Chen X. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020 Aug;108(2):242-247. DOI: 10.1002/cpt.1844Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against lifethreatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512. DOI: 10.1016/j.pharmthera.2020.107512Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against lifethreatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512. DOI: 10.1016/j.pharmthera.2020.107512Avigan [Internet]. [cited 2020 June 04]; Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvwAvigan [Internet]. [cited 2020 June 04]; Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvwFuruta Y et al. Mechanism of Action of T-705 against Influenza Virus. Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. DOI: 10.1128/AAC.49.3.981-986.2005Furuta Y et al. Mechanism of Action of T-705 against Influenza Virus. Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. DOI: 10.1128/AAC.49.3.981-986.2005Sissoko D et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proofof-Concept Trial in Guinea. PLoS Med. 2016 Mar 1;13(3):e1001967. DOI: 10.1371/journal.pmed.1001967Sissoko D et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proofof-Concept Trial in Guinea. PLoS Med. 2016 Mar 1;13(3):e1001967. DOI: 10.1371/journal.pmed.1001967Kerber R et al. Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015 — A Retrospective Observational Study. J Infect Dis. 2019 Jun 19;220(2):195-202. DOI: 10.1093/infdis/jiz078Kerber R et al. Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015 — A Retrospective Observational Study. J Infect Dis. 2019 Jun 19;220(2):195-202. DOI: 10.1093/infdis/jiz078Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. DOI: 10.1097/QCO.0000000000000532Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. DOI: 10.1097/QCO.0000000000000532Fujifilm stock rises as Japan considers Avigan for COVID-19 treatment | 2020-02-25 | BioWorld [Internet]. [cited 2020 May 10]; Available from: https://clck.ru/RDJWbFujifilm stock rises as Japan considers Avigan for COVID-19 treatment | 2020-02-25 | BioWorld [Internet]. [cited 2020 May 10]; Available from: https://clck.ru/RDJWbChina approves first anti-viral drug against coronavirus Covid-19 [Internet]. [cited 2020 May 10]; Available from: https://clck.ru/RDJbJChina approves first anti-viral drug against coronavirus Covid-19 [Internet]. [cited 2020 May 10]; Available from: https://clck.ru/RDJbJCOVID-19 Science Report: Therapeutics [Internet]. [cited 2020 September 24]; Available from: https://clck.ru/RDJgFCOVID-19 Science Report: Therapeutics [Internet]. [cited 2020 September 24]; Available from: https://clck.ru/RDJgFSanders JM et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020 May 12;323(18):1824-1836. DOI: 10.1001/jama.2020.6019Sanders JM et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020 May 12;323(18):1824-1836. DOI: 10.1001/jama.2020.6019Mentré F et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015 Feb;15(2):150-1. DOI: 10.1016/S1473-3099(14)71047-3Mentré F et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015 Feb;15(2):150-1. DOI: 10.1016/S1473-3099(14)71047-3Wang M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DOI: 10.1038/s41422-020-0282-0Wang M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DOI: 10.1038/s41422-020-0282-0Choy K-T et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020 Jun;178:104786. DOI: 10.1016/j.antiviral.2020.104786Choy K-T et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020 Jun;178:104786. DOI: 10.1016/j.antiviral.2020.104786Shannon A et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020 Sep 17;11(1):4682. DOI: 10.1038/s41467020-18463-zShannon A et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020 Sep 17;11(1):4682. DOI: 10.1038/s41467020-18463-zHagar M et al. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations. Int J Mol Sci. 2020 May 30;21(11):3922. DOI: 10.3390/ijms21113922Hagar M et al. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations. Int J Mol Sci. 2020 May 30;21(11):3922. DOI: 10.3390/ijms21113922Han Y et al. Potential inhibitors for the novel coronavirus (SARSCoV-2). Brief Bioinform. 2020 Sep 18;bbaa209. doi: 10.1093/bib/bbaa209Han Y et al. Potential inhibitors for the novel coronavirus (SARSCoV-2). Brief Bioinform. 2020 Sep 18;bbaa209. doi: 10.1093/bib/bbaa209Bibi N et al. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Eur J Pharmacol. 2020 Oct 15;885:173496. DOI: 10.1016/j.ejphar.2020.173496Bibi N et al. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Eur J Pharmacol. 2020 Oct 15;885:173496. DOI: 10.1016/j.ejphar.2020.173496WHO R&D Blueprint COVID-19: Informal consultation on the potential inclusion of Favipiravir in a clinical trial [Internet]. [cited 2020 June 04]; Available from: https://clck.ru/RDJmrWHO R&D Blueprint COVID-19: Informal consultation on the potential inclusion of Favipiravir in a clinical trial [Internet]. [cited 2020 June 04]; Available from: https://clck.ru/RDJmrChen C et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020.03.17.20037432. DOI: 10.1101/2020.03.17.20037432Chen C et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020.03.17.20037432. DOI: 10.1101/2020.03.17.20037432Cai Q et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Mar 18. DOI: 10.1016/j.eng.2020.03.007Cai Q et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Mar 18. DOI: 10.1016/j.eng.2020.03.007Doi Y et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 Sep 21;AAC.01897-20. DOI: 10.1128/AAC.01897-20Doi Y et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 Sep 21;AAC.01897-20. DOI: 10.1128/AAC.01897-20McCullough PA. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19). Antimicrob Agents Chemother. 2020 Sep 23;AAC.02017-20. DOI: 10.1128/AAC.02017-20McCullough PA. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19). Antimicrob Agents Chemother. 2020 Sep 23;AAC.02017-20. DOI: 10.1128/AAC.02017-20Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID- 19. Med J Armed Forces India. 2020 Sep 2. DOI: 10.1016/j.mjafi.2020.08.004Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID- 19. Med J Armed Forces India. 2020 Sep 2. DOI: 10.1016/j.mjafi.2020.08.004Murohashi K et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Respir Investig. 2020 Aug 28;S2212-5345(20)30117-9. DOI: 10.1016/j.resinv.2020.08.001Murohashi K et al. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases. Respir Investig. 2020 Aug 28;S2212-5345(20)30117-9. DOI: 10.1016/j.resinv.2020.08.001Takahashi H et al. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis. 2020 Aug 20;S1201-9712(20)30677-9. DOI: 10.1016/j.ijid.2020.08.047Takahashi H et al. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition. Int J Infect Dis. 2020 Aug 20;S1201-9712(20)30677-9. DOI: 10.1016/j.ijid.2020.08.047Yamamura H et al. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020 Jul 9;24(1):413. DOI: 10.1186/s13054020-03137-5Yamamura H et al. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020 Jul 9;24(1):413. DOI: 10.1186/s13054020-03137-5Preliminary Report of the Favipiravir Observational Study in Japan [Internet]. [cited 2020 September 24]; Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdfPreliminary Report of the Favipiravir Observational Study in Japan [Internet]. [cited 2020 September 24]; Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdfKoshi E et al. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN Case Rep. 2020 Sep 17;1-6. DOI: 10.1007/s13730-020-00534-1Koshi E et al. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. CEN Case Rep. 2020 Sep 17;1-6. DOI: 10.1007/s13730-020-00534-1Tatar E et al. Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia. Transfus Apher Sci. 2020 Aug 3;102904. DOI: 10.1016/j.transci.2020.102904Tatar E et al. Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia. Transfus Apher Sci. 2020 Aug 3;102904. DOI: 10.1016/j.transci.2020.102904Hosoba R et al. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J Clin Exp Hematop. 2020 Sep 3. doi: 10.3960/jslrt.20030.Hosoba R et al. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J Clin Exp Hematop. 2020 Sep 3. doi: 10.3960/jslrt.20030.Inoue H et al. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respir Med Case Rep. 2020;31:101200. DOI: 10.1016/j.rmcr.2020.101200Inoue H et al. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respir Med Case Rep. 2020;31:101200. DOI: 10.1016/j.rmcr.2020.101200Cura Yayla BC et al. Characteristics and Management of Children With COVID-19 in Turkey. Balkan Med J. 2020 Aug 31. DOI: 10.4274/balkanmedj.galenos.2020.2020.7.52Cura Yayla BC et al. Characteristics and Management of Children With COVID-19 in Turkey. Balkan Med J. 2020 Aug 31. DOI: 10.4274/balkanmedj.galenos.2020.2020.7.52Search of: favipiravir | COVID-19 — List Results — ClinicalTrials. gov gov [Internet]. [cited 2020 September 25]; Available from: https://clck.ru/RDJpmSearch of: favipiravir | COVID-19 — List Results — ClinicalTrials. gov gov [Internet]. [cited 2020 September 25]; Available from: https://clck.ru/RDJpmChinese Clinical Trial Register (ChiCTR) — The world health organization international clinical trials registered organization registered platform [Internet]. [cited 2020 September 24]; Available from: https://clck.ru/RDJpmChinese Clinical Trial Register (ChiCTR) — The world health organization international clinical trials registered organization registered platform [Internet]. [cited 2020 September 24]; Available from: https://clck.ru/RDJpm[Internet]. [cited 2020 September 24]; Available from: https://jrct.niph.go.jp/search?page=1[Internet]. [cited 2020 September 24]; Available from: https://jrct.niph.go.jp/search?page=1Реестр разрешений на проведение клинических исследований лекарственных средств. Фавипиравир. [Электронный ресурс]. Доступно по: https://clck.ru/RDFxt Ссылка активна на 25.09.2020Register of permits for conducting clinical trials of medicinal products. Favipiravir. (In Russ). Доступно по: https://clck.ru/RDFxt Ссылка активна на 25.09.2020Ivashchenko AA et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2020 Aug 9;ciaa1176. DOI: 10.1093/cid/ciaa1176Ivashchenko AA et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2020 Aug 9;ciaa1176. DOI: 10.1093/cid/ciaa1176Руженцова Т.А. и др. Возможности этиотропной терапии коронавирусной инфекции вызванной SARS-COV-2, у амбулаторных пациентов // Медицинский оппонент. 2020;1(9):48-58.Ruzhentsova TA et al. Potential for etiotropic therapy of SARS-CoV-2-induced coronavirus disease in outpatients. Medical Opponent = Meditsinskii Opponent. 2020;1(9):48-58. (In Russ).Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) 8-е изд., Москва: Министерство здравоохранения Российской Федерации, 2020. 226 c.The provisional guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 8th ed., Moscow: Ministry of health of the Russian Federation, 2020. 226 p. (In Russ).Jin Y-H et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). Mil Med Res. 2020 Sep 4;7(1):41. DOI: 10.1186/s40779020-00270-8Jin Y-H et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). Mil Med Res. 2020 Sep 4;7(1):41. DOI: 10.1186/s40779020-00270-8Remport Á et al. Az új koronavírus (SARS-CoV-2) okozta fertőzésben szenvedő vese- és májátültetett betegek ellátásának speciális szempontjai. (A COVID–19-pandémia orvosszakmai kérdései). Orv Hetil. 2020 Aug;161(32):1310-1321. DOI: 10.1556/650.2020.31923Remport Á et al. Az új koronavírus (SARS-CoV-2) okozta fertőzésben szenvedő vese- és májátültetett betegek ellátásának speciális szempontjai. (A COVID–19-pandémia orvosszakmai kérdései). Orv Hetil. 2020 Aug;161(32):1310-1321. DOI: 10.1556/650.2020.31923Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against lifethreatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512. DOI: 10.1016/j.pharmthera.2020.107512Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against lifethreatening RNA virus infections. Pharmacol Ther. 2020 May;209:107512. DOI: 10.1016/j.pharmthera.2020.107512PMDA — Report on the Deliberation Results [Internet]. [cited 2020 June 04]; Available from: https://www.pmda.go.jp/files/000210319.pdfPMDA — Report on the Deliberation Results [Internet]. [cited 2020 June 04]; Available from: https://www.pmda.go.jp/files/000210319.pdfPilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir — a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020 Apr 30;6(2):45-51. DOI: 10.1016/S2055-6640(20)30016-9Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir — a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020 Apr 30;6(2):45-51. DOI: 10.1016/S2055-6640(20)30016-9Hase R et al. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. Intern Med. 2020 Sep 15;59(18):2327-2329. DOI: 10.2169/internalmedicine.5377-20Hase R et al. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. Intern Med. 2020 Sep 15;59(18):2327-2329. DOI: 10.2169/internalmedicine.5377-20Singh TU et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020 Sep 5;1-30. DOI: 10.1007/s43440-020-00155-6Singh TU et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020 Sep 5;1-30. DOI: 10.1007/s43440-020-00155-6Kumagai Y et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. DOI: 10.5414/CP202388Kumagai Y et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74. DOI: 10.5414/CP202388Chinello P et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. DOI: 10.1371/journal.pntd.0006034Chinello P et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034. DOI: 10.1371/journal.pntd.0006034Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221. DOI: 10.1177/2048872620922784Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221. DOI: 10.1177/2048872620922784Michaud V et al. Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2020 Sep 5. DOI: 10.1111/cts.12882Michaud V et al. Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2020 Sep 5. DOI: 10.1111/cts.12882Yaylaci S et al. The effects of favipiravir on hematological parameters of covid-19 patients. Rev Assoc Med Bras (1992). 2020 Sep 21;66Suppl 2 (Suppl 2):65-70. DOI: 10.1590/1806-9282.66.S2.65Yaylaci S et al. The effects of favipiravir on hematological parameters of covid-19 patients. Rev Assoc Med Bras (1992). 2020 Sep 21;66Suppl 2 (Suppl 2):65-70. DOI: 10.1590/1806-9282.66.S2.65Soh M et al. Neuroleptic malignant syndrome in patients with COVID-19. Am J Emerg Med. 2020 May 22;S0735-6757(20)30384-3. DOI: 10.1016/j.ajem.2020.05.042Soh M et al. Neuroleptic malignant syndrome in patients with COVID-19. Am J Emerg Med. 2020 May 22;S0735-6757(20)30384-3. DOI: 10.1016/j.ajem.2020.05.042Irie K et al. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19. Clin Transl Sci. 2020 Sep;13(5):880-885. DOI: 10.1111/cts.12827Irie K et al. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19. Clin Transl Sci. 2020 Sep;13(5):880-885. DOI: 10.1111/cts.12827

The authors declare that there are no conflicts of interest present.